extra cellular matrix  (Developmental Studies Hybridoma Bank)

Journal: Addiction Biology

Article Title: Crystallin Alpha B Inhibits Cocaine‐Induced Conditioned Place Preference via the Modulation of Dopaminergic Neurotransmission

doi: 10.1111/adb.70028

Figure Lengend Snippet: CRYAB‐expressing cell types in the cocaine‐administered mice NAcc and reduced Extracellular CRYAB levels in oligodendrocytes in stress‐induced relapse. (A) The mice are injected with cocaine (5 mg/kg [i.p.]). The mice brain sections (10‐μm‐thick) are reacted with anti‐CRYAB (green) and antieach brain cell marker (red). MBP, NeuN, GFAP and IBA1 are markers of oligodendrocytes, neurons, astrocytes and microglia, respectively. Closed arrows indicate the colocalization of each marker and CRYAB. Open arrows indicate the non‐colocalization of each marker and CRYAB. Original magnification is 200X. The scale bar is 25 μm. (B) The CRYAB protein levels are measured in culture media of primary human oligodendrocytes by using ELISA kit. Primary human oligodendrocytes are cultured in control or cocaine‐treated media (1 or 10 μM) for 24 h, followed by treatment with corticosterone (200 ng/mL) for 1 h. Data are expressed as the mean ± SE ( n = 4 for each cocaine‐treated group without corticosterone, corticosterone control and 1‐μM cocaine‐treated group with corticosterone, respectively; n = 6 for 10 μM cocaine‐treated group with corticosterone) and are analysed using two‐way repeated measure ANOVA followed by the Holm–Sidak post hoc t test (** p < 0.01 vs. each control, ## p < 0.01 vs. each cocaine at the same treatment dose). NAcc, nucleus accumbens.

Article Snippet: Primary human oligodendrocytes (36055‐22, Celprogen, Torrance, CA, United States) were seeded into 24‐well plates (E36055‐22‐24 Well, Celprogen) at a density of 1 × 10 5 cells/well.

Techniques: Expressing, Injection, Marker, Enzyme-linked Immunosorbent Assay, Cell Culture, Control

Journal: PLOS ONE

Article Title: Recovery after human bone marrow mesenchymal stem cells (hBM-MSCs)-derived extracellular vesicles (EVs) treatment in post-MCAO rats requires repeated handling

doi: 10.1371/journal.pone.0312298

Figure Lengend Snippet: (a–c) Characterization and quantification of human-bone marrow mesenchymal stem cell (hBM-MSC)-derived extracellular vesicles (EVs). (a) Nanosight Tracking analyses (NTA) showing the size distribution pattern of EVs. (b) Western blots of hBM-MSCs marker (GM130) and EVs markers (ALIX, CD9, CD81). “Wash” lane represents the negative control. Each image comes from different blots. (c) Representative image of EVs using transmission electron microscopy (TEM). Scale bar 100 nm. (d–f) In vivo tracking of ExoGlow-labeled EVs demonstrated that EVs reach the brain and accumulate near the stroke injury 6 hours after administration at 2 dps. (d) Timeline of intranasal single dose treatment of ExoGlow-labeled EVs (~2.4 x 10 9 EVs in 200 μl), starting 2 dps and collecting the tissue 6 hours after. (e) Representative coronal section after a single intranasal administration of ExoGlow-labeled EVs (~2.4 x 10 9 EVs in 200 μl) at 2 dps. Hoechst indicates cell nuclei. Scale bars 4 mm and 100 μm. (f) Quantification of the average size of ExoGlow+ particles in the ipsilateral and contralateral hemispheres. Data was analyzed using a paired t-test (*p<0.05). Bars show mean +/− SD. Each symbol represents the average size of ExoGlow+ particles from all ROIs in each hemisphere (5 ROIs/hemisphere in each rat) of a single rat ( n = 4 ).

Article Snippet: Human bone marrow mesenchymal stem cells (hBM-MSCs) were purchased from Celprogren (frozen vial with ~1.2 x 10 6 cells; #36094–22) and plated on human mesenchymal bone marrow stem cell culture extracellular expansion matrix pre-coated T75 Flasks (Celprogen, #E36094-21-T75) following Celprogren recommendations.

Techniques: Derivative Assay, Western Blot, Marker, Negative Control, Transmission Assay, Electron Microscopy, In Vivo, Labeling